| Audit Committee | Position |
|---|---|
|
|
Chair
|
|
|
Member
|
|
Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Docker, Inc. is a leading provider of containerization technology that enables developers to build, share, and run applications across any environment seamlessly. His prior experience includes various sales leadership roles with Confluent from early 2019 through the end of 2023, and as Managing Director for Skywind Games' Asia Pacific operations from 2016 to 2022. Mr. Goodman also has held positions with Dropbox, Hootsuite, and OFX, where he has established a strong track record in strategic sales, market expansion, and operational leadership. |
Member
|
|
Audit Committee Charter |
Download |
| Compensation Committee | Position |
|---|---|
|
|
Chair
|
|
|
Member
|
|
Compensation Committee Charter |
Download |
| Nominating and Corporate Governance Committee | Position |
|---|---|
|
|
Chair
|
|
|
Member
|
| Strategy and Alternatives, Risk, Safety and Regulatory Committee | Position |
|---|---|
|
|
Member
|
|
|
Member
|
|
Professor Lawrence Steinman is currently is the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University. His specialities lie in autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. In the Steinman Laboratory of Stanford, which is his foundation, he has developed new therapies for autoimmune diseases, some of which are in advanced clinical trials. Professor Steinman has overseen success in the pharmaceuticals industry; he was on the board of Centocor, sold to Johnson and Johnson in 1998 for $4.9 billion, and was a founder of Neurocrine Biosciences (NASDAQ:NBIX) which went public in 1997. Professor Steinman was instrumental in discovering the application of natalizumab (Tysabri) in treating multiple sclerosis. The drug was sold to Royalty Pharma in 2017 for $2.85 billion. Recognition for his work includes the Friedrich Sasse Award in 1994, the John Dystel Prize in 2004, the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011, and the Anthony Cerami Award in Translational Medicine in 2015. He has twice been awarded the Senator Jacob Javits Award by the US Congress, in 1988 and 2002. Professor Steinman is a member of both the National Academy of Medicine and the National Academy of Sciences. |
Member
|
|
Strategy and Alternatives, Risk, Safety and Regulatory Committee Charter |
Download |
Omar Jimenez
Ryan Smith
Jay Goodman
Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Docker, Inc. is a leading provider of containerization technology that enables developers to build, share, and run applications across any environment seamlessly. His prior experience includes various sales leadership roles with Confluent from early 2019 through the end of 2023, and as Managing Director for Skywind Games' Asia Pacific operations from 2016 to 2022. Mr. Goodman also has held positions with Dropbox, Hootsuite, and OFX, where he has established a strong track record in strategic sales, market expansion, and operational leadership.
Ryan Smith
Omar Jimenez
Ryan Smith
Omar Jimenez
Omar Jimenez
Ryan Smith
Prof Lawrence Steinman
Professor Lawrence Steinman is currently is the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University.
His specialities lie in autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica.
In the Steinman Laboratory of Stanford, which is his foundation, he has developed new therapies for autoimmune diseases, some of which are in advanced clinical trials.
Professor Steinman has overseen success in the pharmaceuticals industry; he was on the board of Centocor, sold to Johnson and Johnson in 1998 for $4.9 billion, and was a founder of Neurocrine Biosciences (NASDAQ:NBIX) which went public in 1997.
Professor Steinman was instrumental in discovering the application of natalizumab (Tysabri) in treating multiple sclerosis. The drug was sold to Royalty Pharma in 2017 for $2.85 billion.
Recognition for his work includes the Friedrich Sasse Award in 1994, the John Dystel Prize in 2004, the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011, and the Anthony Cerami Award in Translational Medicine in 2015.
He has twice been awarded the Senator Jacob Javits Award by the US Congress, in 1988 and 2002.
Professor Steinman is a member of both the National Academy of Medicine and the National Academy of Sciences.